GEAP202416409A - Exatecan derivatives and antibody-drug conjugates thereof - Google Patents

Exatecan derivatives and antibody-drug conjugates thereof

Info

Publication number
GEAP202416409A
GEAP202416409A GEAP202416409A GEAP2024016409A GEAP202416409A GE AP202416409 A GEAP202416409 A GE AP202416409A GE AP202416409 A GEAP202416409 A GE AP202416409A GE AP2024016409 A GEAP2024016409 A GE AP2024016409A GE AP202416409 A GEAP202416409 A GE AP202416409A
Authority
GE
Georgia
Prior art keywords
exatecan
derivatives
antibody
drug conjugates
conjugated
Prior art date
Application number
GEAP202416409A
Other languages
English (en)
Georgian (ka)
Inventor
Janika Cheuk-Ing Wong
Marija Vrljic
Peter Strop
Jaume Pons
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of GEAP202416409A publication Critical patent/GEAP202416409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GEAP202416409A 2021-05-07 2022-05-06 Exatecan derivatives and antibody-drug conjugates thereof GEAP202416409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185736P 2021-05-07 2021-05-07
US202163248705P 2021-09-27 2021-09-27
US202263321187P 2022-03-18 2022-03-18

Publications (1)

Publication Number Publication Date
GEAP202416409A true GEAP202416409A (en) 2024-02-26

Family

ID=81851425

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416409A GEAP202416409A (en) 2021-05-07 2022-05-06 Exatecan derivatives and antibody-drug conjugates thereof

Country Status (15)

Country Link
US (1) US20250101032A1 (https=)
EP (1) EP4334322A1 (https=)
JP (1) JP2024518438A (https=)
KR (1) KR20240036506A (https=)
AU (1) AU2022269073A1 (https=)
BR (1) BR112023023276A2 (https=)
CA (1) CA3219236A1 (https=)
CL (1) CL2023003304A1 (https=)
CO (1) CO2023016939A2 (https=)
GE (1) GEAP202416409A (https=)
IL (1) IL308246A (https=)
MX (1) MX2023013118A (https=)
PE (1) PE20241299A1 (https=)
TW (1) TW202309042A (https=)
WO (1) WO2022236136A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CA3241734A1 (en) * 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
EP4489790A1 (en) * 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药（苏州）有限公司 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
KR20250075560A (ko) 2022-07-15 2025-05-28 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-trop2 항체 및 이의 접합체
KR20250049293A (ko) * 2022-07-27 2025-04-11 밍훼이 파마슈티컬 (항저우) 리미티드 항체-약물 접합체 및 이의 용도
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
CN117024438A (zh) * 2022-07-29 2023-11-10 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
JP2025511436A (ja) * 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
EP4594327A1 (en) 2022-09-30 2025-08-06 BeiGene Switzerland GmbH Ligand-drug conjugate of exatecan analogue, and medical use thereof
PE20252282A1 (es) * 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
WO2024130161A2 (en) 2022-12-16 2024-06-20 Bionecure Therapeutics Inc Novel camptothecin derivatives and conjugates thereof
IL321193A (en) * 2022-12-28 2025-07-01 Adcendo Aps Antibody-drug conjugates targeting UPARAP including extacan derivatives
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
CN116063311B (zh) * 2023-03-01 2025-09-26 金麦安博生物制药(苏州)有限公司 一种依喜替康衍生物及其制备方法
CN120916790A (zh) * 2023-03-27 2025-11-07 台湾浩鼎生技股份有限公司 Trop2耦合生物分子、医药组合物及方法
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
EP4687996A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687995A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN119080792A (zh) * 2023-09-15 2024-12-06 杭州爱科瑞思生物医药有限公司 依沙替康羟胺衍生物及其应用
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
CN117417347A (zh) * 2023-09-28 2024-01-19 杭州爱科瑞思生物医药有限公司 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
CN117645608A (zh) * 2023-11-30 2024-03-05 昆山新蕴达生物科技有限公司 抗体药物偶联物及其应用
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
CN117986269A (zh) * 2024-01-18 2024-05-07 苏州提领生物制药有限公司 喜树碱衍生物及其制备方法和应用
WO2025167722A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2025207828A1 (en) * 2024-03-26 2025-10-02 Fulgent Pharma Llc Nanocomposition comprising modified exatecan and use thereof
WO2025233501A1 (en) * 2024-05-10 2025-11-13 Astrazeneca Ab Conjugates comprising a topoisomerase i inhibitor
WO2025247302A1 (zh) * 2024-05-31 2025-12-04 杭州中美华东制药有限公司 一种喜树碱类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3466976T1 (sl) * 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN111620927B (zh) * 2019-05-20 2022-11-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物中间体的一锅法制备工艺
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.

Also Published As

Publication number Publication date
CA3219236A1 (en) 2022-11-10
MX2023013118A (es) 2024-02-27
CO2023016939A2 (es) 2024-05-10
US20250101032A1 (en) 2025-03-27
TW202309042A (zh) 2023-03-01
EP4334322A1 (en) 2024-03-13
JP2024518438A (ja) 2024-05-01
AU2022269073A1 (en) 2023-11-23
KR20240036506A (ko) 2024-03-20
CL2023003304A1 (es) 2024-04-19
WO2022236136A1 (en) 2022-11-10
PE20241299A1 (es) 2024-06-24
BR112023023276A2 (pt) 2024-01-30
IL308246A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
GEAP202416409A (en) Exatecan derivatives and antibody-drug conjugates thereof
PE20230467A1 (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CO2019006455A2 (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
PE20170517A1 (es) Conjugados de anticuerpo-farmaco-anti-ptk7
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20170917A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
PH12016502509A1 (en) Her2 antibody-drug conjugates
PA8626201A1 (es) Conjugados de caliqueamicina
MX2022013768A (es) Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
MX2022005452A (es) Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2.
CO2025007425A2 (es) Derivados de exatecan y conjugados de anticuerpo y fármaco de estos
CL2023002775A1 (es) Conjugados de amatoxina y anticuerpo específicos de linfocitos b
MX2022015147A (es) Conjugados de anticuerpos biespecíficos-fármacos dirigidos al receptor del factor de crecimiento epidérmico (egfr) y glicoproteína de transmembrana de tipo 1 (muc1) y usos de los mismos.
MX2022008437A (es) Conjugados fármaco-anticuerpo específicos de sitio con enlazadores que contienen péptidos.
MX2025004144A (es) Anticuerpo anti-gucy2c y usos del mismo